Biondo Investment Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-155,152
| Closed | -$7.18M | – | 89 |
|
|
2025
Q2 | $7.18M | Buy |
155,152
+6,259
| +4% | +$307K | 0.95% | 36 |
|
|
2025
Q1 | $9.08M | Buy |
148,893
+6,693
| +5% | +$390K | 1.29% | 32 |
|
|
2024
Q4 | $8.04M | Buy |
142,200
+1,260
| +0.9% | +$70.4K | 1.11% | 37 |
|
|
2024
Q3 | $7.29M | Buy |
140,940
+5,671
| +4% | +$266K | 1% | 38 |
|
|
2024
Q2 | $5.62M | Buy |
135,269
+5,306
| +4% | +$237K | 0.83% | 40 |
|
|
2024
Q1 | $7.05M | Buy |
129,963
+4,583
| +4% | +$233K | 1.09% | 36 |
|
|
2023
Q4 | $6.43M | Sell |
125,380
-260
| -0.2% | -$13.6K | 1.09% | 36 |
|
|
2023
Q3 | $7.29M | Buy |
125,640
+6,523
| +5% | +$400K | 1.37% | 28 |
|
|
2023
Q2 | $7.62M | Buy |
119,117
+2,799
| +2% | +$188K | 1.41% | 29 |
|
|
2023
Q1 | $8.06M | Buy |
116,318
+510
| +0.4% | +$36K | 1.63% | 25 |
|
|
2022
Q4 | $8.33M | Sell |
115,808
-952
| -0.8% | -$71.8K | 1.86% | 22 |
|
|
2022
Q3 | $8.3M | Buy |
116,760
+1,866
| +2% | +$135K | 1.91% | 20 |
|
|
2022
Q2 | $8.85M | Buy |
114,894
+3,340
| +3% | +$254K | 1.95% | 20 |
|
|
2022
Q1 | $8.15M | Buy |
111,554
+5,133
| +5% | +$345K | 1.44% | 27 |
|
|
2021
Q4 | $6.63M | Buy |
106,421
+8,857
| +9% | +$520K | 1.11% | 32 |
|
|
2021
Q3 | $5.77M | Buy |
97,564
+1,450
| +2% | +$95.5K | 0.99% | 36 |
|
|
2021
Q2 | $6.42M | Buy |
96,114
+4,608
| +5% | +$300K | 1.1% | 27 |
|
|
2021
Q1 | $5.78M | Buy |
91,506
+2,772
| +3% | +$172K | 1.15% | 34 |
|
|
2020
Q4 | $5.5M | Buy |
88,734
+1,592
| +2% | +$97.9K | 1.05% | 33 |
|
|
2020
Q3 | $5.25M | Buy |
87,142
+3,111
| +4% | +$187K | 1.14% | 31 |
|
|
2020
Q2 | $4.94M | Buy |
84,031
+15,995
| +24% | +$957K | 1.25% | 30 |
|
|
2020
Q1 | $3.79M | Buy |
68,036
+1,148
| +2% | +$70.2K | 1.26% | 32 |
|
|
2019
Q4 | $4.29M | Buy |
66,888
+3,725
| +6% | +$213K | 0.99% | 36 |
|
|
2019
Q3 | $3.2M | Buy |
63,163
+860
| +1% | +$40.4K | 0.82% | 40 |
|
|
2019
Q2 | $2.83M | Buy |
62,303
+2,465
| +4% | +$115K | 0.67% | 43 |
|
|
2019
Q1 | $2.85M | Buy |
59,838
+2,835
| +5% | +$141K | 0.72% | 42 |
|
|
2018
Q4 | $2.96M | Sell |
57,003
-665
| -1% | -$35.7K | 0.89% | 34 |
|
|
2018
Q3 | $3.58M | Sell |
57,668
-62,875
| -52% | -$3.73M | 0.85% | 37 |
|
|
2018
Q2 | $6.67M | Buy |
120,543
+3,578
| +3% | +$193K | 1.68% | 17 |
|
|
2018
Q1 | $7.4M | Buy |
116,965
+305
| +0.3% | +$19.6K | 1.93% | 14 |
|
|
2017
Q4 | $7.15M | Buy |
116,660
+1,667
| +1% | +$104K | 1.81% | 15 |
|
|
2017
Q3 | $7.33M | Buy |
114,993
+2,535
| +2% | +$148K | 2.02% | 14 |
|
|
2017
Q2 | $6.27M | Sell |
112,458
-11,909
| -10% | -$648K | 1.81% | 17 |
|
|
2017
Q1 | $9.15M | Buy |
124,367
+17,539
| +16% | +$962K | 3.27% | 7 |
|
|
2016
Q4 | $6.24M | Sell |
106,828
-19,092
| -15% | -$1.04M | 2.06% | 13 |
|
|
2016
Q3 | $6.79M | Buy |
125,920
+1,113
| +0.9% | +$71.5K | 2.3% | 13 |
|
|
2016
Q2 | $9.18M | Buy |
124,807
+2,424
| +2% | +$171K | 3.28% | 7 |
|
|
2016
Q1 | $7.82M | Buy |
122,383
+50,725
| +71% | +$3.2M | 2.96% | 9 |
|
|
2015
Q4 | $4.93M | Sell |
71,658
-185
| -0.3% | -$12.2K | 1.64% | 16 |
|
|
2015
Q3 | $4.25M | Buy |
71,843
+743
| +1% | +$47.1K | 1.41% | 20 |
|
|
2015
Q2 | $4.73M | Buy |
71,100
+1,670
| +2% | +$110K | 1.42% | 20 |
|
|
2015
Q1 | $4.48M | Buy |
69,430
+2,320
| +3% | +$145K | 1.33% | 19 |
|
|
2014
Q4 | $3.96M | Buy |
67,110
+1,065
| +2% | +$60.1K | 1.19% | 21 |
|
|
2014
Q3 | $3.38M | Buy |
66,045
+2,846
| +5% | +$142K | 1.04% | 23 |
|
|
2014
Q2 | $3.07M | Buy |
63,199
+4,350
| +7% | +$214K | 0.97% | 24 |
|
|
2014
Q1 | $3.06M | Buy |
58,849
+6,663
| +13% | +$355K | 1.01% | 22 |
|
|
2013
Q4 | $2.77M | Buy |
52,186
+4,521
| +9% | +$230K | 0.95% | 23 |
|
|
2013
Q3 | $2.21M | Buy |
47,665
+5,709
| +14% | +$251K | 0.84% | 25 |
|
|
2013
Q2 | $1.88M | Buy |
+41,956
| New | +$1.82M | 0.81% | 24 |
|
Other funds holding BMY
Biondo Investment Advisors's BMY Position: Q3 2025 in Review
Biondo Investment Advisors sold out of Bristol-Myers Squibb (BMY) in Q3 2025, closing a stake of 155,152 shares — an estimated $7.18M sold.
Biondo Investment Advisors first reported a position in BMY in Q2 2013 and held it in 49 quarters. The position peaked at $9.18M in Q2 2016. 2,267 funds tracked by Wall St. Rank hold BMY as of Q3 2025.
- Biondo Investment Advisors reported no remaining Bristol-Myers Squibb position as of Q3 2025 after selling out during the quarter.
- Biondo Investment Advisors sold 155,152 Bristol-Myers Squibb shares in Q3 2025, an estimated $7.18M.
- Biondo Investment Advisors first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 49 quarters.
- Biondo Investment Advisors's Bristol-Myers Squibb position peaked at $9.18M in Q2 2016.
- 2,267 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2025.
Based on Biondo Investment Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.